MedTrace Logo

Nivolumab+Ipilimumab+RT in MSS mCRC

NCT04575922 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-09-08

No results posted yet for this study

Summary

This research is being done to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in people with metastatic microsatellite stable colorectal cancer.

This research study involves the following drugs and interventions:

* Ipilimumab
* Nivolumab
* Radiation Therapy

Conditions

  • Metastatic Microsatellite Stable Colorectal Cancer

Interventions

DRUG

Nivolumab

Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.

DRUG

Ipilimumab

Administered into vein by intravenous infusion day 1 of each 6 week study cycle.

RADIATION

Radiation Therapy

3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.

Sponsors & Collaborators

Principal Investigators

  • Theodore S Hong, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2023-12-31
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575922 on ClinicalTrials.gov